Cargando…
Diagnostic Properties of Three SARS-CoV-2 Antibody Tests
Serological assays emerged as complementary tools to RT-PCR in the diagnosis of SARS-CoV-2 as well as being needed for epidemiological studies. This study aimed to assess the performance of a rapid test (RT) compared to that of serological tests using finger prick blood samples. A total of 183 sampl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393643/ https://www.ncbi.nlm.nih.gov/pubmed/34441375 http://dx.doi.org/10.3390/diagnostics11081441 |
_version_ | 1783743772576710656 |
---|---|
author | Basgalupp, Suelen dos Santos, Giovana Bessel, Marina Garcia, Lara de Moura, Ana Carolina Rocha, Ana Carolina Brito, Emerson de Miranda, Giovana Dornelles, Thayane Dartora, William Pellanda, Lucia Hallal, Pedro Wendland, Eliana |
author_facet | Basgalupp, Suelen dos Santos, Giovana Bessel, Marina Garcia, Lara de Moura, Ana Carolina Rocha, Ana Carolina Brito, Emerson de Miranda, Giovana Dornelles, Thayane Dartora, William Pellanda, Lucia Hallal, Pedro Wendland, Eliana |
author_sort | Basgalupp, Suelen |
collection | PubMed |
description | Serological assays emerged as complementary tools to RT-PCR in the diagnosis of SARS-CoV-2 as well as being needed for epidemiological studies. This study aimed to assess the performance of a rapid test (RT) compared to that of serological tests using finger prick blood samples. A total of 183 samples were evaluated, 88 of which were collected from individuals with negative RT-PCR and 95 from positive RT-PCR individuals. The diagnostic performance of RT (WONDFO(®)) and LUMIT (PROMEGA(®)) were compared to that of ELISA (EUROIMMUN(®)) for detecting antibodies against SARS-CoV-2 according to time from symptoms onset. The IgG antibody tests were detected in 77.4% (LUMIT), 77.9% (RT), and 80.0% (ELISA) of individuals. The detection of antibodies against SARS-CoV-2 increases in accordance with increasing time from symptoms onset. Considering only time from symptoms onset >21 days, the positivity rate ranged from 81.8 to 97.0% between the three tests. The RT and LUMIT showed high agreement with ELISA (agreement = 91.5%, k = 0.83, and agreement = 96.3%, k = 0.9, respectively) in individuals who had symptoms 15 to 21 days before sample collection. Compared to that of the ELISA assay, our results show sensitivity ranged from 95% to 100% for IgG antibody detection in individuals with symptoms onset between 15 and 21 days before sample collection. The specificity was 100% in individuals with symptoms onset >15 days before serological tests. This study shows good performance and high level of agreement of three immunoassays for the detection of SARS-CoV-2 antibodies. |
format | Online Article Text |
id | pubmed-8393643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83936432021-08-28 Diagnostic Properties of Three SARS-CoV-2 Antibody Tests Basgalupp, Suelen dos Santos, Giovana Bessel, Marina Garcia, Lara de Moura, Ana Carolina Rocha, Ana Carolina Brito, Emerson de Miranda, Giovana Dornelles, Thayane Dartora, William Pellanda, Lucia Hallal, Pedro Wendland, Eliana Diagnostics (Basel) Article Serological assays emerged as complementary tools to RT-PCR in the diagnosis of SARS-CoV-2 as well as being needed for epidemiological studies. This study aimed to assess the performance of a rapid test (RT) compared to that of serological tests using finger prick blood samples. A total of 183 samples were evaluated, 88 of which were collected from individuals with negative RT-PCR and 95 from positive RT-PCR individuals. The diagnostic performance of RT (WONDFO(®)) and LUMIT (PROMEGA(®)) were compared to that of ELISA (EUROIMMUN(®)) for detecting antibodies against SARS-CoV-2 according to time from symptoms onset. The IgG antibody tests were detected in 77.4% (LUMIT), 77.9% (RT), and 80.0% (ELISA) of individuals. The detection of antibodies against SARS-CoV-2 increases in accordance with increasing time from symptoms onset. Considering only time from symptoms onset >21 days, the positivity rate ranged from 81.8 to 97.0% between the three tests. The RT and LUMIT showed high agreement with ELISA (agreement = 91.5%, k = 0.83, and agreement = 96.3%, k = 0.9, respectively) in individuals who had symptoms 15 to 21 days before sample collection. Compared to that of the ELISA assay, our results show sensitivity ranged from 95% to 100% for IgG antibody detection in individuals with symptoms onset between 15 and 21 days before sample collection. The specificity was 100% in individuals with symptoms onset >15 days before serological tests. This study shows good performance and high level of agreement of three immunoassays for the detection of SARS-CoV-2 antibodies. MDPI 2021-08-10 /pmc/articles/PMC8393643/ /pubmed/34441375 http://dx.doi.org/10.3390/diagnostics11081441 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Basgalupp, Suelen dos Santos, Giovana Bessel, Marina Garcia, Lara de Moura, Ana Carolina Rocha, Ana Carolina Brito, Emerson de Miranda, Giovana Dornelles, Thayane Dartora, William Pellanda, Lucia Hallal, Pedro Wendland, Eliana Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title | Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title_full | Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title_fullStr | Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title_full_unstemmed | Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title_short | Diagnostic Properties of Three SARS-CoV-2 Antibody Tests |
title_sort | diagnostic properties of three sars-cov-2 antibody tests |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393643/ https://www.ncbi.nlm.nih.gov/pubmed/34441375 http://dx.doi.org/10.3390/diagnostics11081441 |
work_keys_str_mv | AT basgaluppsuelen diagnosticpropertiesofthreesarscov2antibodytests AT dossantosgiovana diagnosticpropertiesofthreesarscov2antibodytests AT besselmarina diagnosticpropertiesofthreesarscov2antibodytests AT garcialara diagnosticpropertiesofthreesarscov2antibodytests AT demouraanacarolina diagnosticpropertiesofthreesarscov2antibodytests AT rochaanacarolina diagnosticpropertiesofthreesarscov2antibodytests AT britoemerson diagnosticpropertiesofthreesarscov2antibodytests AT demirandagiovana diagnosticpropertiesofthreesarscov2antibodytests AT dornellesthayane diagnosticpropertiesofthreesarscov2antibodytests AT dartorawilliam diagnosticpropertiesofthreesarscov2antibodytests AT pellandalucia diagnosticpropertiesofthreesarscov2antibodytests AT hallalpedro diagnosticpropertiesofthreesarscov2antibodytests AT wendlandeliana diagnosticpropertiesofthreesarscov2antibodytests |